Hormone receptor-positive (HR-positive) metastatic breast cancer is an MBC subtype that tests positive for estrogen receptors, progesterone receptors, or both. HR-positive MBC can be either positive or negative for the HER2 receptor.
While HR-positive MBC is typically sensitive to hormone therapy, it often develops treatment resistance to hormone therapy. See below to read research on newer hormone therapies, targeted therapies like CDK4/6 inhibitors, mTOR inhibitors, PI3K inhibitors, and other therapy combinations for HR-positive MBC.
- Dana-Farber Cancer Institute: 2020 EMBRACE Metastatic Breast Cancer Virtual Forum Series | Research Update for ER-Positive MBC
- The American Journal of Managed Care: First-line Therapy for HR-Positive, HER2-Negative MBC
- Dana-Farber Cancer Institute: ER-Positive Breast Cancer: What’s New in Treatment and Research at MBC Patient Forum 2019
- Targeted Oncology: Expert Reviews Novel Strategies in the Pipeline for the Treatment of ER-Positive Breast Cancer
- UpToDate: Treatment Approach to Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: Endocrine Therapy and Targeted Agents
Clinical Trials for Hormone Receptor-Positive MBC
- Metastatic Trial Search: Clinical Trials for HR-Positive Breast Cancer
Last Modified on April 5, 2021